Institute for International Research

By attending, you will learn how to: Solve expression and production bottlenecks with innovative molecular engineering approaches Boost therapeutic function by using molecular recognition scaffolds Discover new tools for improving therapeutic formulations Explore the spectrum of tools, generic and novel, that may enhance your process development workflow Plus, Non-Antibody Protein Therapeutic Development and Production is conveniently co-located with the Antibody Development and Production Conference, giving you the additional opportunity to explore the expanded exhibit hall featuring the latest array of technologies and services on the market and the chance to network with over 400 industry leaders all under one roof. Get the most out of your budget with our dual conference pass Arrive in Carlsbad early and take advantage of the best value dual conference pass. This pass will give you access and materials to all co-located events taking place on March 2-6, 2009 at the La Costa Resort & Spa: Technology Transfer for Biopharmaceuticals Process Validation for Biopharmaceuticals Outsourcing Manufacturing for Biopharmaceuticals Biopharmaceutical Development & Production Week events allow you to walk away with all the information you need to move your company forward in the biopharmaceutical marketplace in one trip.

IBC's Non-Antibody Protein Therapeutics Development & Production conference covers development and production of molecules that do not benefit from the affinity characteristics of antibodies. You will be able to find the solutions you need to your specific, intractable expression, purification, and production challenges.

Meet the People Who Matter to You

You will join fellow development scientists, process development scientists and engineers, and executives from virtual protein therapeutic start-up companies, CMOs, and medium to large biotechnology and pharmaceutical companies to discuss development and production issues that are critical to you in the non-antibody protein therapeutics market.

Key opinion leaders and pioneering innovators present case studies to help you to resolve critical issues facing you today, such as:

• Increasing expression and capture yields
• Expression and purification of intractable proteins
• Ensuring appropriate glycosylation
• Evaluation and correction of conformational variance
• Resolution of unique formulation considerations

Keynote Presentation:
Changing of the Guard? Alternatives to Animal Cells for the Expression of Therapeutic Glycoproteins David Robinson, Ph.D., Executive Director, Bioprocess Research and Development, Merck & Co., Inc.

New Reports and Strategies:

• Novel Strategies for Molecular Engineering
• Non-Antibody Scaffolds for Molecular Recognition
• Risk and Regulatory Management Strategies
• Pathways for Leveraging Alternative Expression Systems to Resolve Critical Challenges
• VLP, Viral Vectors & Vaccines
• Recent Advances in Purification: Improving Yield, Activity, and Cost
• Expanding the Protein Therapeutic Formulation Toolbox & Design Space
• Generic Tools for Unique Processes

Case Studies from Industry Leaders Including:

• Microbial Expression Toolbox for Process Development/Manufacture of Protein Biotherapeutics from Lonza Biologics
• An Optimized Non-Antibody Platform for Protein Therapeutics from Amunix
• Development Risk Management in Vaccine Manufacturing from Eden Biodesign
• Selecting and Developing a Viral Vector Manufacturing Process from Genzyme Corporation
• Assessing Product Potency & Related Characteristics of Gardasil®, a Recombinant HPV Vaccine from Merck Research Laboratories
• Purifying Candidate Therapeutic Proteins without Affinity Chromatography from Genzyme Corporation
• Avoiding Pitfalls in Protein PEGgylation from Avecia Biologics
• High Throughput Residual DNA Analysis: A Q-PCR Based Approach from Genzyme Corporation